Cleveland Biolabs (Nasdaq: CBLI) 58.3% HIGHER; reported strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502 in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE